in-PharmaTechnologist.com's periodic round-up of developments in the pharmaceutical manufacturing space includes the expansion plans of two Malaysian companies and lay-offs in Ireland.
Pharmaniaga pursues Indonesian plant
Malaysian generics manufacturer Pharmaniaga has earmarked around $93m for the purchase of a manufacturing plant in Indonesia as it looks to expand its operations this year.
Indonesia is the company's second largest market after Malaysia and Pharmaniaga has now signaled its intent to further establish its manufacturing presence in the nation.
This move is not to increase market share in Indonesia but is part of the company's plan to expand exports which was discussed at the annual general meeting.
Speaking after the meeting, Datuk Azman Yahya, chairman of Pharmaniaga, said: "We are very keen to acquire a manufacturing outfit in Indonesia and we are looking for opportunities in the country."
The company has now hired a firm to help it find a plant capable of producing $25m to $31m worth of products a year. This would be a significant addition to the $62m worth of products currently manufactured at Pharmaniaga's three Indonesian plants.
Corden PharmaChem temporary lay-offs
Corden PharmaChem has temporarily laid-off 61 of its 105 employees at its manufacturing facility in Cork, Ireland following an explosion last month.
One worker was killed in the explosion at the site which produces active pharmaceutical ingredients and also offers contract manufacturing services.
An internal investigation into the explosion is underway, with Corden expecting the site to be operational again in July.
Nisvizh expands packaging capacity
Nisvizh Pharmaceutical Plant, a government-backed pharmaceutical firm in Belarus, is in the process of installing its second 'Bottlepack' plastic blow-fill-seal line.
This will increase the factories capacity to 10m bottles, in 250ml and 500ml sizes. Coupled to the increase in capacity is a desire to export its plastic packaged pharma products to new markets. The firm already sells products in Russia, Moldova, Kazakhstan, Uzbekistan and Tajikistan.
CCM pharmaceutical expansion
The Chemical Company of Malaysia is pumping $41.9m into expanding its pharmaceutical division.
Of this $15.5m has been allocated to expanding the pharmaceutical manufacturing capacity at the company's Bangi facility, with a further $23m being used to improve its manufacturing and warehousing facilities in Klang.